POST-MARKETING TOLERABILITY/SAFETY ASSESSMENT OF PYLERA® VS LANSOPRAZOLE/AMOXICILLIN/CLARITHROMYCIN COMBO THERAPY: HISTORICAL DATABASE COHORT STUDY

(1) UNIVERSITÉ DE BORDEAUX

(2) Axcan Pharma Inc

(3) Axcan Pharma US, Inc



This item was part of the H.pylori I session at UEG Week Stockholm 2011

This item can be cited as: Gut 2011; 60 (Suppl 3) A169